NCT03726320

Brief Summary

Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the U.S. This randomized trial will evaluate the efficacy of a Community Health Worker-led decision coaching program to facilitate Shared Decision Making (SDM) and Prostate Specific Antigen (PSA) screening among Black men with regards to decision quality, the decision making process, patient-provider communication and PSA utilization for Black men in the primary care setting.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
162

participants targeted

Target at P50-P75 for not_applicable prostate-cancer

Timeline
Completed

Started Oct 2019

Typical duration for not_applicable prostate-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 7, 2018

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 31, 2018

Completed
12 months until next milestone

Study Start

First participant enrolled

October 15, 2019

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 21, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2023

Completed
8 months until next milestone

Results Posted

Study results publicly available

May 23, 2024

Completed
Last Updated

May 23, 2024

Status Verified

May 1, 2024

Enrollment Period

3.5 years

First QC Date

September 7, 2018

Results QC Date

March 29, 2024

Last Update Submit

May 22, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • Prostate Specific Antigen (PSA) Screening Rates

    Percentage of participants who receive at least one PSA screening. Screening data are collected through patient self-reports and electronic health record data.

    Up to Month 3

  • Patient Knowledge Survey Score

    The Patient Knowledge Survey comprises 12 items assessing participants' understanding of PSA testing and prostate cancer. Respondents provide an answer of "True," "Unsure," or "False." The total score is the sum of correct responses and ranges from 0-12; higher scores indicate greater knowledge.

    Day 1

  • Decision Quality Score

    Scale consists of 12 items assessing participants' attitudes toward prostate cancer treatment and screening (6 Pros and 6 Cons of testing) scored on a 5 point Likert scale (Strongly Disagree to Strongly Agree). The total score is the sum of responses and ranges from -24 to +24; Positive scores indicate a more favorable assessment of the pros versus the cons of the test.This survey will be administered twice: once directly following the coaching session prior to the patient's appointment, and again following the appointment.

    Day 1

  • Percentage of Participants Who Make Informed Choice

    Percentage of participants who made an Informed Choice to either undergo or decline PSA testing. Informed choices are those in which: 1\. Men with good knowledge and positive measure of informed choice attitudes (\> or = 22) choose to undergo the test OR 2) Men with good knowledge but negative measure of informed choice attitudes (\<22) towards the test, do not undergo the test The Measure of Informed Choice Attitudes survey is administered twice: once directly following the coaching session prior to the patient's appointment, and again following the appointment and the patient's screening decision is recorded during post-appointment.

    Day 1

Secondary Outcomes (6)

  • Decision Self-Efficacy Scale Score

    Day 1

  • Doctor-Patient Communication Survey Score

    Day 1

  • Perceived Efficacy in Patient-Physician Interactions Questionnaire (PEPPI) Score

    Day 1

  • Change in Decisional Conflict Scale Score

    Day 1

  • Satisfaction With Decision Scale Score

    Day 1

  • +1 more secondary outcomes

Study Arms (2)

Intervention Group

EXPERIMENTAL

A decision aid along with decision coaching on PSA screening from a Community Health Worker (CHW). The intervention will be administered directly prior to the participant's appointment with their provider.

Behavioral: Education Counseling Session for PSA Screening

Control Group

ACTIVE COMPARATOR

A decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control. The intervention will be administered directly prior to the participant's appointment with their provider.

Behavioral: General Health Counseling Coaching

Interventions

counseling from extensively trained CHW

Intervention Group

coaching using an educational tool focused on dietary and lifestyle modification

Control Group

Eligibility Criteria

Age40 Years - 69 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsGender Identity
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients:
  • Black
  • Male
  • Attending FQHC for routine primary care appointment
  • Providers:
  • Provider at Sunset Park Health Council Federally Qualified Health Center (FQHC)

You may not qualify if:

  • Provider at Sunset Park Health Council Federally Qualified Health Center (FQHC)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

Related Publications (1)

  • Makarov DV, Feuer Z, Ciprut S, Lopez NM, Fagerlin A, Shedlin M, Gold HT, Li H, Lynch G, Warren R, Ubel P, Ravenell JE. Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers. Trials. 2021 Feb 10;22(1):128. doi: 10.1186/s13063-021-05064-4.

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Results Point of Contact

Title
Danil Makarov
Organization
NYU Langone Health

Study Officials

  • Danil Makarov, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 7, 2018

First Posted

October 31, 2018

Study Start

October 15, 2019

Primary Completion

April 21, 2023

Study Completion

September 20, 2023

Last Updated

May 23, 2024

Results First Posted

May 23, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will share

Aggregate participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).

Shared Documents
STUDY PROTOCOL
Time Frame
Immediately following publication. No end date.
Access Criteria
Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting requests and accessing data may be found at (Link to be provided).Researchers who provide a methodologically sound proposal will have access to the data.

Locations